ANALYSIS OF T-CELL STIMULATION BY SUPERANTIGEN PLUS MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II MOLECULES OR BY CD3 MONOCLONAL-ANTIBODY - COSTIMULATION BY PURIFIED ADHESION LIGANDS VCAM-1, ICAM-1, BUT NOT ELAM-1

被引:332
作者
VANSEVENTER, GA
NEWMAN, W
SHIMIZU, Y
NUTMAN, TB
TANAKA, Y
HORGAN, KJ
GOPAL, TV
ENNIS, E
OSULLIVAN, D
GREY, H
SHAW, S
机构
[1] OTSUKA AMER PHARMACEUT INC, DEPT ENDOTHELIAL CELL BIOL, ROCKVILLE, MD 20850 USA
[2] OTSUKA AMER PHARMACEUT INC, DEPT MOLEC BIOL, ROCKVILLE, MD 20850 USA
[3] UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA
[4] NIAID, PARASIT DIS LAB, BETHESDA, MD 20892 USA
[5] CYTEL CORP, LA JOLLA, CA 92037 USA
关键词
D O I
10.1084/jem.174.4.901
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Many ligands of adhesion molecules mediate costimulation of T cell activation. The generality of this emerging concept is best determined by using model systems which exploit physiologically relevant ligands. We developed such an "antigen-specific" model system for stimulation of resting CD4+ human T cells using the following purified ligands: (a) major histocompatibility complex class II plus the superantigen Staphylococcus enterotoxin A, to engage the T cell receptor (TCR); (b) adhesion proteins vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and endothelial leukocyte adhesion molecule 1 (ELAM-1), to provide potential cell surface costimulatory signals; and (c) recombinant interleukin 1-beta (rIL-1-beta)/rIL-6 as costimulatory cytokines. In this biochemically defined system, we find that resting CD4+ T cells require costimulation in order to respond to TCR engagement. This costimulation can be provided by VCAM-1 or ICAM-1; however adhesion alone is not sufficient since ELAM-1 mediates adhesion but not costimulation. The cytokines IL-1-beta and IL-6 by themselves cannot mediate costimulation, but augment the adhesion ligand-mediated costimulation. Direct comparison with the model of TCR/CD3 engagement by CD3 monoclonal antibody demonstrated comparable costimulatory requirements in both system, thereby authenticating the commonly used CD3 model. The costimulation mediated by the activation-dependent interaction of the VLA-4 and LFA-1 integrins with their respective ligands VCAM-1 and ICAM-1 leads to increased IL-2R-alpha (CD25) expression and proliferation in both CD45RA+ CD4+ and CD45RO+ CD4+ T cells. The integrins also regulate the secretion of IL-2, IL-4, and granulocyte/macrophage colony-stimulating factor. In contrast the activation-independent adhesion of CD4+ T cell to ELAM-1 molecules does not lead to T cell stimulation as measured by proliferation, IL-2R-alpha expression, or cytokine release. These findings imply that adhesion per se is not sufficient for costimulation, but rather that the costimulation conferred by the VLA-4/VCAM-1 and LFA-1/ICAM-1 interactions reflects specialized accessory functions of these integrin pathways. The new finding that VLA-4/VCAM-1 mediates costimulation adds significance to observations that VCAM-1 is expressed on a unique set of potential antigen-presenting cells in vivo.
引用
收藏
页码:901 / 913
页数:13
相关论文
共 69 条
[1]  
BACCHETTA R, 1990, J IMMUNOL, V144, P902
[2]   ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE-1 - AN INDUCIBLE RECEPTOR FOR NEUTROPHILS RELATED TO COMPLEMENT REGULATORY PROTEINS AND LECTINS [J].
BEVILACQUA, MP ;
STENGELIN, S ;
GIMBRONE, MA ;
SEED, B .
SCIENCE, 1989, 243 (4895) :1160-1165
[3]   A FUNCTIONAL DICHOTOMY IN CD4+ LYMPHOCYTES-T [J].
BOTTOMLY, K .
IMMUNOLOGY TODAY, 1988, 9 (09) :268-274
[4]  
BUTCHER EC, 1989, FUNDAMENTAL IMMUNOLO, P117
[5]  
CERDAN C, 1991, J IMMUNOL, V146, P560
[6]  
CLAYBERGER C, 1987, J IMMUNOL, V138, P1510
[7]  
COLSON YL, 1990, J IMMUNOL, V144, P2975
[8]   STIMULATION OF CLONED HUMAN LYMPHOCYTES-T VIA THE CD3 OR CD28 MOLECULES INDUCES ENHANCEMENT IN VASCULAR ENDOTHELIAL PERMEABILITY TO MACROMOLECULES WITH PARTICIPATION OF TYPE-1 AND TYPE-2 INTERCELLULAR-ADHESION PATHWAYS [J].
DAMLE, NK ;
DOYLE, LV .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (09) :1995-2003
[9]  
DAVIS L, 1986, J IMMUNOL, V136, P3588
[10]  
DAVIS LS, 1990, J IMMUNOL, V145, P785